NPs and PAs who practice in dermatology
After completing this activity, learners should be better able to:
Identify novel agents for moderate to severe psoriasis and their selectivity within the JAK-STAT pathway
Detail key elements of agents targeting the JAK-STAT pathway that differentiate their place in therapy from currently available treatments for moderate to severe psoriasis
Educate patients on the safety profile differences for TYK2 and JAK inhibitors for moderate to severe psoriasis
All faculty and planners participating in continuing education activities sponsored Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Victoria Garcia-Albea, NP, DCNP: consultant/advisor/speaker: Sanofi-Genzyme.
Steven Feldman, MD, PhD: consultant/speaker: AbbVie, Accordant, Almirall, Alvotech, Amgen, Arcutis, Arena, Argenx, Biocon, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Forte, Helsinn, Janssen, Leo, Lilly, Mylan, Novartis, Pfizer, Samsung, Sanofi, Sun Pharma, Union Chimique Belge (UCB), vTv Therapeutics, Voluntis; researcher: Galderma, Janssen, Lilly, Pfizer, Regeneron; stock/stock options: Sensal Health.
Kristine Kucera, PA-C, MPAS, DHSc: consultant/advisor/speaker: AbbVie, Amgen, Beiersdorf, Bristol Myers Squibb, Dermavant, Janssen, LEO Pharma, Novartis, Sun Pharma, UCB.
The planners and content peer reviewers from Partners for Advancing Clinical Education and Practicing Clinicians Exchange do not have any relevant financial relationships to disclose, except Victoria Garcia-Albea, NP, DCNP as noted above.
Learners wishing to earn CE/CME credit must:
The estimated time to complete this activity is 1.00 hour.
This activity has been made available online.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Partners for Advancing Clinical Education, Practicing Clinicians Exchange or any educational supporter.
Joint Accreditation Statement
In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
NP course advisor: Victoria Garcia-Albea, NP, DCNP, Lahey Hospital and Medical Center, Burlington, Massachusetts
AAPA Credit Designation
Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until January 16, 2024. PAs should only claim credit commensurate with the extent of their participation.
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credits for learning and change.